SANA Quote, Financials, Valuation and Earnings

CEL-SCI has a net margin of -- compared to Sana Biotechnology's net margin of --. Sana Biotechnology's return on equity of -- beat CEL-SCI's return on equity of --.

Sana Biotechnology has a consensus price target of $9.40, signalling upside risk potential of 449.71%. On the other hand CEL-SCI has an analysts' consensus of $7.73 which suggests that it could grow by 1694.28%. Given that CEL-SCI has higher upside potential than Sana Biotechnology, analysts believe CEL-SCI is more attractive than Sana Biotechnology.

Sana Biotechnology has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison CEL-SCI has a beta of 0.653, suggesting its less volatile than the S&P 500 by 34.718%.

Sana Biotechnology has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CEL-SCI offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sana Biotechnology pays -- of its earnings as a dividend. CEL-SCI pays out -- of its earnings as a dividend.

Sana Biotechnology quarterly revenues are --, which are smaller than CEL-SCI quarterly revenues of --. Sana Biotechnology's net income of -$59.9M is lower than CEL-SCI's net income of -$6.9M. Notably, Sana Biotechnology's price-to-earnings ratio is -- while CEL-SCI's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sana Biotechnology is -- versus -- for CEL-SCI. Usually stocks with elevated PS ratios are considered overvalued.

Foghorn Therapeutics has a net margin of -- compared to Sana Biotechnology's net margin of -244.9%. Sana Biotechnology's return on equity of -- beat Foghorn Therapeutics's return on equity of --.

Sana Biotechnology has a consensus price target of $9.40, signalling upside risk potential of 449.71%. On the other hand Foghorn Therapeutics has an analysts' consensus of $12.50 which suggests that it could grow by 150%. Given that Sana Biotechnology has higher upside potential than Foghorn Therapeutics, analysts believe Sana Biotechnology is more attractive than Foghorn Therapeutics.

Sana Biotechnology has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Foghorn Therapeutics has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Sana Biotechnology has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Foghorn Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sana Biotechnology pays -- of its earnings as a dividend. Foghorn Therapeutics pays out -- of its earnings as a dividend.

Sana Biotechnology quarterly revenues are --, which are smaller than Foghorn Therapeutics quarterly revenues of $7.8M. Sana Biotechnology's net income of -$59.9M is lower than Foghorn Therapeutics's net income of -$19.1M. Notably, Sana Biotechnology's price-to-earnings ratio is -- while Foghorn Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sana Biotechnology is -- versus 9.35x for Foghorn Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Moderna has a net margin of -- compared to Sana Biotechnology's net margin of 0.7%. Sana Biotechnology's return on equity of -- beat Moderna's return on equity of -17.44%.

Sana Biotechnology has a consensus price target of $9.40, signalling upside risk potential of 449.71%. On the other hand Moderna has an analysts' consensus of $74.19 which suggests that it could grow by 75.88%. Given that Sana Biotechnology has higher upside potential than Moderna, analysts believe Sana Biotechnology is more attractive than Moderna.

Sana Biotechnology has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Moderna has a beta of 1.597, suggesting its more volatile than the S&P 500 by 59.715%.

Sana Biotechnology has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Moderna offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sana Biotechnology pays -- of its earnings as a dividend. Moderna pays out -- of its earnings as a dividend.

Sana Biotechnology quarterly revenues are --, which are smaller than Moderna quarterly revenues of $1.9B. Sana Biotechnology's net income of -$59.9M is lower than Moderna's net income of $13M. Notably, Sana Biotechnology's price-to-earnings ratio is -- while Moderna's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sana Biotechnology is -- versus 3.23x for Moderna. Usually stocks with elevated PS ratios are considered overvalued.

Omega Therapeutics has a net margin of -- compared to Sana Biotechnology's net margin of -629.56%. Sana Biotechnology's return on equity of -- beat Omega Therapeutics's return on equity of -171.4%.

Sana Biotechnology has a consensus price target of $9.40, signalling upside risk potential of 449.71%. On the other hand Omega Therapeutics has an analysts' consensus of $9.00 which suggests that it could grow by 1030.95%. Given that Omega Therapeutics has higher upside potential than Sana Biotechnology, analysts believe Omega Therapeutics is more attractive than Sana Biotechnology.

Sana Biotechnology has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Omega Therapeutics has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Sana Biotechnology has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Omega Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sana Biotechnology pays -- of its earnings as a dividend. Omega Therapeutics pays out -- of its earnings as a dividend.

Sana Biotechnology quarterly revenues are --, which are smaller than Omega Therapeutics quarterly revenues of $2.6M. Sana Biotechnology's net income of -$59.9M is lower than Omega Therapeutics's net income of -$16.4M. Notably, Sana Biotechnology's price-to-earnings ratio is -- while Omega Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sana Biotechnology is -- versus 5.72x for Omega Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.